04/09/2019
We are actively recruiting for a research study to potentially help individuals with co***ne dependence. The study is a Phase I dose-ranging, placebo-controlled, double blind study assessing the safety and preliminary efficacy of an anti-co***ne vaccine called "dAd5GNE vaccine". The vaccine evokes an immune system response and stimulates the creation of anti-co***ne antibodies. The antibodies bind to the co***ne molecules when a person takes co***ne and prevents the co***ne molecules from reaching the brain. This co***ne-antibody complex is not able to cross the blood brain barrier and thus eliminates the effects of co***ne on the brain, as seen in pre-clinical studies done by our group. The study will take place over a period of approximately 32 weeks.